Core--Peptide synthesis

核心--多肽合成

• 批准号: 6212122
• 负责人: FRANCES M FINN
• 金额: --
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-08-01 至 2004-07-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6212122
• 关键词: biomedical facility; high performance liquid chromatography; peptide chemical synthesis; protein purification

Description: (Applicant's Description) The Peptide Synthesis Facility began operations in December of 1988. The Facility was established for the purpose of providing members of the University of Pittsburgh Cancer Institute with peptides for their research. The Facility is under the direction of Dr. Frances Finn, who has had many years of experience in the field of peptide synthesis. The Peptide Synthesis Facility occupies 600 square feet of space on the 12th floor of Scaife Hall in the School of Medicine. Equipment to establish the Facility was purchased with a BRS shared instrument grant from NIH. This included an Applied Biosystems 430A Synthesizer, equipment of High Performance Liquid Chromatography, both analytical and preparative scale. An Applied Biosystems Synergy Synthesizer was purchased by the UPCI in 1997, to meet the increased demand for peptides, especially small amounts for screening purposes. Synthesis, quality control, purification, and equipment maintenance are the responsibility of the operator, a technician who has been with the Facility since 1990. He is responsible for the producing peptides of a high degree of purity. The operational plan is based on the assumption that fewer operation difficulties occur if a single experienced individual has responsibility for the equipment. Dr. Finn oversees the operation of the facility, troubleshooting difficult synthetic sequences, consulting with investigators as to optimal sequences for antigen coupling, the necessity for purification, predicted solubility of peptides and general peptide handling and storage practices. An Advisory Committee discusses management of the Facility especially in regard to allocation of time on the instrument, establishment of fee structures and personnel appointments.

描述：（申请人的描述）肽合成设施于1988年12月开始运行。 该设施的建立是为了向匹兹堡大学癌症研究所的成员提供肽用于他们的研究。 该设施由Frances Finn博士领导，他在肽合成领域拥有多年经验。 肽合成设施占地600平方英尺的空间，位于医学院斯凯夫大厅的12楼。建立该设施的设备是用NIH的BRS共享仪器赠款购买的。 这包括Applied Biosystems 430A合成仪，高效液相色谱设备，分析和制备规模。 UPCI于1997年购买了一台Applied Biosystems Synergy Synthesizer，以满足对肽的需求，特别是用于筛选目的的少量肽。合成、质量控制、纯化和设备维护是操作员的责任，操作员是自1990年以来一直在该设施工作的技术人员。他负责生产高纯度的肽。 操作计划是基于这样的假设，即如果由一个有经验的人负责设备，则操作困难较少。 Finn博士监督设施的运行，排除困难的合成序列，与研究人员就抗原偶联的最佳序列，纯化的必要性，肽的预测溶解度以及一般肽处理和储存实践进行咨询。一个咨询委员会讨论机制的管理问题，特别是在文书时间分配、收费结构的建立和人员任命方面。